Premium
Mass psychogenic response to human papillomavirus vaccination
Author(s) -
Buttery Jim P,
Madin Simon,
Crawford Nigel W,
Elia Sonja,
La Vincente Sophie,
Hanieh Sarah,
Smith Lindsay,
Bolam Bruce
Publication year - 2008
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2008.tb02018.x
Subject(s) - medicine , population , general hospital , family medicine , public health , pediatrics , nursing , environmental health
The Medical Journal of Australia ISSN: 0025729X 1 September 2008 189 5 261-262 ©The Medical Journal of Australia 2008 www.mja.com.au Public Health for females aged 12–26 years. The initial phase targ ary schools, vaccinating girls aged 12–17 years in Y and 12. This program was conducted by local vaccination teams in Victoria. The rea togenicity of 4vHPV reported in clini acceptable, with serious adverse events following i (AEFI) reported in less than 0.1% of vaccine r erv (H ea C ical cancer associated with human papillomavirus PV) affects approximately 1000 Australian women ch year, causing about 300 deaths. The newly licensed HPV vaccines Gardasil (CSL Limited), a quadrivalent vaccine (4vHPV), and Cervarix (GlaxoSmithKline Vaccines), a bivalent vaccine (2vHPV), induce protection against the two most common strains of HPV, which cause 70% of all cervical cancers. The quadrivalent HPV vaccine was included in the government-funded National Immunisation Program from April 2007 eted secondears 7, 10, 11 government